Emperor preserved trial: Empagliflozin effective to treat heart failure - Video

Published On 2022-02-10T19:30:06+05:30 | Updated On 10 Feb 2022 7:31 PM IST

Overview

The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic stable heart failure with preserved ejection fraction, irrespective of diabetes status.

Incidence of Heart Failure in India appears to rise and estimates of prevalence range from 1.3 million to 4.6 million, with an annual incidence of 0.49–1.8 million. Several drugs are being investigated to manage heart failure.

The safety and efficacy of empagliflozin in patients with symptomatic heart failure was assessed in 2997 Patients randomized in a 1:1 design to either empagliflozin 10 mg or matching placebo of 2,991 patients in the trial.

Health-related quality of life in patients treated with empagliflozin had significant improvement in patients with meaningful improvements was reported in American College of Cardiology journal. Most routinely used drugs for Heart failure with reduced ejection fraction have not shown to be effective among patients, however this drug marks the change of treatment options.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751